+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bedeutung der immunochemotherapie fur das uberleben von patienten mit metastasiertem nierenzellkarzinom - Eine retrospektive studie der therapie-gruppen interferon-alpha2a/vinblastin vs. interferon-alpha2a/interleukin-2/5-fluorouracil



Bedeutung der immunochemotherapie fur das uberleben von patienten mit metastasiertem nierenzellkarzinom - Eine retrospektive studie der therapie-gruppen interferon-alpha2a/vinblastin vs. interferon-alpha2a/interleukin-2/5-fluorouracil



Urologe A 43(9): 1111-1119



The prognosis for patients with metastatic RCC remains unsatisfactory to date. Despite the data from a recently published study, the role of the therapy combinations IFN-alpha2aNBL und IFN-alpha2a/IL-2/5-FU did not seem clearly defined. Therefore, we compared the impact of combined immunochemotherapy on remission and survival as well as the safety profile in a retrospective single-center study. 105 patients with metastatic RCC having received treatment between 1992 and 2002 with either s.c.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011799916

Download citation: RISBibTeXText


Related references

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. Scandinavian Journal of Gastroenterology 34(2): 194-198, 1999

A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Alimentary Pharmacology & Therapeutics 19(3): 339-347, 2004

Is immunological therapy useful in chronic hepatitis C virus infection? A randomized study of interferon alpha2a plus cimetidine versus interferon alpha2a plus placebo. Hepatology 32(4 Pt 2): 443A, 2000

Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease. Rheumatology 43(10): 1275-1282, 2004

Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis. Advances in Experimental Medicine and Biology 528: 521-523, 2003

First-line-therapie fur deutsche patienten mit metastasiertem nierenzellkarzinom im EORTC-protokoll 30012. Urologe A 43(8): 992-993, 2004

Recombinant interferon-alpha2a plus 5-fluorouracil for the treatment of metastatic melanoma. Melanoma Research 7(6): 513-516, 1998

Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection. Antiviral Therapy 13(7): 851-862, 2008

Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts. Clinical Cancer Research 1(1): 33-40, 1995

Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta. Der Urologe. Ausg. a 46(5): 528-534, 2007

Human recombinant interferon-alpha2a and interferon-alphaA/D have different effects on bleomycin-induced lung injury. Respiration; International Review of Thoracic Diseases 68(2): 169-177, 2001

Extracorporeal photopheresis alone and with interferon-alpha2a in chronic hepatitis C patients who failed previous interferon therapy. Digestive Diseases and Sciences 44(5): 1020-1026, 1999

Interferon alpha2a in combination with lamivudine in the treatment of patients with chronic HbeAg hepatitis B non-responders to interferon monotherapy. Journal of Hepatology 36(Supplement 1): 245, 2002

Kleinhirninfarkte und Kleinhirnblutungen. Eine vergleichende, retrospektive Studie an 78 Patienten. Aktuelle Neurologie 18(03): 88-94, 1991

Systemische 5-Fluorouracil-(Kombinatons)-Chemo- therapie bei Patienten mit metastasiertem kolorektalem Karzinom. Der Onkologe 5(1): 39-46, 1999